Bioventus (BVS) Is Up 6.1% After Reaffirming 2026 Sales Outlook And Strong Q2 Earnings Jump
Bioventus Inc. (BVS) reported strong Q2 2026 results with a significant jump in net income and reaffirmed its full-year 2026 sales guidance of US$600 million to US$610 million. The company's investment narrative focuses on converting modest sales growth into higher profitability while managing debt. Analysts project Bioventus's revenue to reach $697.6 million and earnings to hit $47.7 million by 2029, suggesting a fair value of $14.80.
Bioventus (BVS) Stock Jumps On Profit Strength As Growth Risks Remain
Bioventus (BVS) stock surged 13.7% following a strong Q2 earnings report, showcasing adjusted EBITDA of US$35 million on US$153.2 million revenue and healthy cash generation. While the company's profitability and cash flow are positive, concerns remain regarding its reliance on a narrow product set, leverage, and execution risks with new platforms. Management reaffirmed full-year revenue guidance and is working towards deleveraging, but bears point to a decline in some segments and potential uncertainty from a strategic review.
Bioventus, Inc.: Bioventus Reports Second Quarter Financial Results
Bioventus Inc. reported strong second-quarter 2026 financial results, with reported revenue increasing 4% to $153.2 million and GAAP earnings per diluted share rising significantly to $0.47. The company reaffirmed its full-year 2026 guidance for revenue, Adjusted Diluted EPS, and cash from operations, and announced that its Board of Directors has initiated a review of strategic alternatives to maximize shareholder value. This decision follows an unsolicited acquisition proposal and other expressions of interest.
Bioventus Shareholder Notice
Faruqi & Faruqi, LLP is investigating potential claims against Bioventus Inc. (NASDAQ: BVS) and reminds investors of the March 13, 2023 deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that Bioventus's offering documents and public statements contained materially false and misleading information regarding the company's liquidity, rebate practices, and financial controls, leading to significant stock price drops. Investors who suffered losses exceeding $100,000 are encouraged to contact Faruqi & Faruqi.
Bioventus (Nasdaq: BVS) posts Q2 profit surge and weighs strategic options
Bioventus Inc. (Nasdaq: BVS) reported a significant surge in Q2 2026 net income to $33.4 million, up from $7.5 million year-over-year, driven by strong net sales of $153.2 million and the removal of a deferred tax asset valuation allowance. The company reaffirmed its full-year 2026 guidance and announced that its board is reviewing strategic alternatives, including a potential sale, following an unsolicited acquisition proposal and other expressions of interest. This review aims to maximize shareholder value, with advice from Evercore and Latham & Watkins.
5 Growth Stocks That Pass Peter Lynch's Favorite Test
This article identifies five growth stocks that align with Peter Lynch's investment philosophy, combining valuation discipline with strong financial health and growth prospects. It explains a screening methodology using the P/E ratio, Piotroski F-score, and five-year earnings growth rate to find companies like National Vision Holdings, Newmark Group, dLocal, Opera, and Bioventus. The author emphasizes that while screens provide a starting point, thorough research is crucial before investing.
Bioventus Shareholder Action Reminder
Faruqi & Faruqi, LLP is investigating potential claims against Bioventus Inc. (NASDAQ: BVS) and reminds investors of the March 13, 2023 deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that Bioventus's initial public offering documents and subsequent public statements contained materially false and misleading information regarding the company's liquidity, rebate practices, and financial prospects, leading to significant stock price declines. Investors who suffered losses exceeding $100,000 are encouraged to contact the law firm to discuss their legal options.
Bioventus Shareholder Action Reminder
Faruqi & Faruqi, LLP is investigating potential claims against Bioventus Inc. (NASDAQ: BVS) and reminds investors of the March 13, 2023 deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that Bioventus's offering documents and public statements contained materially false and misleading information regarding the company's liquidity, rebate practices, and financial prospects. Investors who suffered losses exceeding $100,000 are encouraged to contact the firm.
Bioventus Deadline Alert
Faruqi & Faruqi, LLP is investigating potential claims against Bioventus Inc. (NASDAQ: BVS) and reminds investors of the March 13, 2023 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit. The lawsuit alleges that Bioventus made materially false and misleading statements regarding its business, operations, and compliance policies, specifically related to liquidity issues, unsustainable rebate practices, and deficient disclosure controls. Investors who suffered losses exceeding $100,000 between February 11, 2021, and November 21, 2022, are encouraged to contact the law firm.
BlackRock (BVS) discloses 3.4M-share, 5.02% passive stake in Bioventus
BlackRock, Inc. has disclosed a passive ownership stake of 5.02% in Bioventus Inc.'s Class A stock, totaling 3,404,523 shares. This information was reported via a Schedule 13G filing, indicating BlackRock holds sole voting power over 3,350,552 shares and sole dispositive power over all 3,404,523 shares. The filing specifies that no single BlackRock client holds more than five percent of Bioventus' outstanding common shares.
Bioventus, Inc. Class A Actuals & Estimates (LSX:A2APNA)
This article provides an overview of Bioventus, Inc. Class A (A2APNA) stock, including its current price, historical performance, and analyst forecasts. It also details financial actuals and estimates for income, balance sheet, and cash flow, along with information on earnings, revenue, dividends, market capitalization, and employee count. The stock saw a 3.45% increase in the past 24 hours, and analysts have a price target range of 12.06 EUR to 13.79 EUR.
A2APNA Forecast — Price Target — Prediction for 2027
This article provides an in-depth forecast for Bioventus, Inc. Class A (A2APNA) stock, including analyst price targets, past performance, and future earning estimates. It details current stock price, market capitalization, revenue, net income, and confirms that the company does not pay dividends.
A2APNA Stock Price and Chart — LSX:A2APNA
This article provides an overview of Bioventus, Inc. Class A (A2APNA) stock listed on the Lang & Schwarz Exchange, including key financial stats, upcoming earnings, and analyst insights. It details the company's business segments focusing on orthobiologics and musculoskeletal treatments. The content also addresses frequently asked questions regarding its stock ticker, forecast, financial reports, dividend policy, and employee count.
A2APNA Forecast — Price Target — Prediction for 2027
This article provides a forecast for Bioventus, Inc. Class A (A2APNA) stock, including price targets from 5 analysts. It also covers financial metrics like EPS, revenue, net income, and EBITDA, along with frequently asked questions about the company's stock, earnings, and dividends. The next earnings report for Bioventus, Inc. Class A is expected on August 11, 2026.
Debt to assets ratio of Bioventus, Inc. Class A – LS:A2APNA
The article provides financial information for Bioventus, Inc. Class A (LS:A2APNA) on TradingView. It specifically highlights the debt to assets ratio for the company. The content also mentions the data sources and copyright information.
Cash flow from financing activities of Bioventus, Inc. Class A – LS:A2APNA
This article provides financial data specifically on the cash flow from financing activities of Bioventus, Inc. Class A, traded under the symbol LS:A2APNA. The content is presented within the TradingView platform, noting the market status as closed with no trades. It highlights the availability of historical financial information from various data providers.
Cash per share of Bioventus, Inc. Class A – LS:A2APNA
This article provides financial information for Bioventus, Inc. Class A (LS:A2APNA), specifically focusing on its cash per share. It appears to be a financial data page from TradingView, including general market information and links to various financial tools and community features.
Return on equity % of Bioventus, Inc. Class A – LS:A2APNA
The article provides a financial overview of Bioventus, Inc. Class A (A2APNA) on TradingView, specifically focusing on its Return on Equity (ROE) percentage. It indicates that the market was closed at the time of access and no trades were recorded. The content is part of a larger financial data platform, offering various tools and community features.
Total revenue of Bioventus, Inc. Class A – LS:A2APNA
This article provides financial information for Bioventus, Inc. Class A under the ticker LS:A2APNA on TradingView. It specifically highlights the "Total revenue" section within the financial data for the company. The content appears to be a stub or a section of a larger financial data page, showing navigation and general information about the company's financial overview.
EBITDA of Bioventus, Inc. Class A – LS:A2APNA
This article displays the EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) for Bioventus, Inc. Class A (LS:A2APNA) on TradingView. It provides financial data for the company, indicating the period, value, and percentage change. The article focuses solely on presenting this financial metric within the TradingView platform.
Bioventus, Inc. Class A Statistics – LS:A2APNA
This page provides financial statistics and ratios for Bioventus, Inc. Class A (LS:A2APNA) on the Lang & Schwarz Tradecenter, including valuation, profitability, liquidity, solvency ratios, and per-share metrics. Users can access annual or quarterly data going back to 2013, though many data points are currently marked as unavailable. The platform offers a hub for investors to analyze the company's financial health and performance.
Cash flow from investing activities of Bioventus, Inc. Class A – LS:A2APNA
This article displays the cash flow from investing activities for Bioventus, Inc. Class A (LS:A2APNA) on TradingView. It appears to be a financial data page rather than a traditional article, providing access to financial information without detailed textual analysis. The content is primarily a listing of navigation and data source acknowledgments.
Bioventus, Inc. Class A Income Statement – LS:A2APNA
This article presents the income statement for Bioventus, Inc. Class A (A2APNA), indicating the total revenue for the last quarter was 114.33 million EUR, a 14.96% decrease from the previous quarter. The net income for Q1 2026 was 2.69 million EUR. The report includes an overview of financial statements, statistics, and dividend information.
Equity in earnings of Bioventus, Inc. Class A – LS:A2APNA
This article provides details on the equity in earnings for Bioventus, Inc. Class A (LS:A2APNA), as listed on the Lang & Schwarz Tradecenter. It indicates that the market is currently closed with no trades recorded. The page includes general market and financial data overview, with core content revolving around the "Equity in earnings" metric for the specified company.
Price to sales forward of Bioventus, Inc. Class A – LS:A2APNA
The article focuses on the "Price to sales forward" metric for Bioventus, Inc. Class A, traded under the symbol A2APNA on the Lang & Schwarz Tradecenter. It provides an overview of the financial data available for this company through TradingView, noting that the market was closed at the time of publication and no trades were recorded.
Price to earnings forward of Bioventus, Inc. Class A – LS:A2APNA
This page from TradingView provides financial information for Bioventus, Inc. Class A (LS:A2APNA), specifically focusing on its forward price-to-earnings ratio. The content indicates that market data is provided by ICE Data Services and FactSet, with SEC filings from Quartr. It is a market data page rather than an analytical article.
Bioventus, Inc. Class A Dividends – LS:A2APNA
The article provides a financial overview of Bioventus, Inc. Class A (LS:A2APNA) on TradingView. It indicates that the market is currently closed with no trades, and offers information on the company's financials, including dividends, earnings, and revenue.
EBITDA margin % of Bioventus, Inc. Class A – LS:A2APNA
This article focuses on the EBITDA margin percentage of Bioventus, Inc. Class A, identified by the ticker LS:A2APNA on TradingView. It provides financial data for the company under the "Markets" section, specifically for German stocks in Health Technology and Medical Specialties. The page indicates that the market is currently closed with no trades.
CapEx per share of Bioventus, Inc. Class A – LS:A2APNA
The article focuses on the "CapEx per share" metric for Bioventus, Inc. Class A (LS:A2APNA). It appears to be a financial data page from TradingView, providing an overview of the company's capital expenditure per share. The content includes navigation elements common to a financial platform but lacks detailed textual analysis of the metric itself.
Bioventus, Inc. Class A Cash Flow – LS:A2APNA
This article provides key financial data for Bioventus, Inc. Class A (LS:A2APNA), focusing on its cash flow activities. It highlights that the free cash flow for Q1 2026 was €7.24 million, and for the full year 2025, it was €60.80 million with an operating cash flow of €62.98 million. The data is presented annually from 2013 through 2025 for operating, investing, and financing cash flows.
Enterprise value of Bioventus, Inc. Class A – LS:A2APNA
This page provides financial information for Bioventus, Inc. Class A (LS:A2APNA) on TradingView. It indicates that the market is currently closed without any trades. The page specifies that market and reference data are provided by ICE Data Services and FactSet, respectively.
Bioventus, Inc. Class A Revenue Breakdown – LS:A2APNA
This article provides a revenue breakdown for Bioventus, Inc. Class A, trading under the symbol A2APNA on Lang & Schwarz Tradecenter. It highlights that the company generated 483.68 million EUR last year, with Pain Treatments being its highest-performing segment. The United States was the largest contributor to its revenue.
Bioventus, Inc. Class A Earnings and Revenue – LS:A2APNA
Bioventus, Inc. Class A (A2APNA) reported strong financial results for the last quarter, with EPS of 0.13 EUR, significantly exceeding the 0.06 EUR estimate. The company also surpassed revenue expectations, bringing in 114.33 M EUR against an estimated 112.44 M EUR. Analysts are forecasting continued growth for the next quarter, with anticipated EPS of 0.19 EUR and revenue of 136.11 M EUR.
Cost of goods sold of Bioventus, Inc. Class A – LS:A2APNA
The article focuses on the cost of goods sold for Bioventus, Inc. Class A (LS:A2APNA), providing financial data on this specific metric. It indicates that the information is "Made by humans" and sources market data from ICE Data Services and reference data from FactSet.
Pretax income of Bioventus, Inc. Class A – LS:A2APNA
The article focuses on the pretax income of Bioventus, Inc. Class A, identified by its stock symbol LS:A2APNA on the Lang & Schwarz Tradecenter. It indicates that the market is currently closed and no trades have occurred for this stock. The content appears to be a financial data page from TradingView, providing an overview of the company's financial status.
Operating cash flow per share of Bioventus, Inc. Class A – LS:A2APNA
This article provides the operating cash flow per share for Bioventus, Inc. Class A (LS:A2APNA). It is a financial data point presented on TradingView, which offers various market tools and information. The data itself is presented without further analysis or context beyond its numerical value.
Bioventus, Inc. Class A Revenue Breakdown – DUS:4B8
Bioventus, Inc. Class A (DUS:4B8) generated 483.68 million EUR in revenue last year. The Pain Treatments segment was the top-performing segment, contributing 237.60 million EUR. The United States was the largest regional contributor, accounting for 427.49 million EUR.
Average basic shares outstanding of Bioventus, Inc. Class A – DUS:4B8
This article provides financial data for Bioventus, Inc. Class A (DUS:4B8) on the Dusseldorf Stock Exchange. Specifically, it focuses on the "Average basic shares outstanding" for the company. The content appears to be a stub or a data point from a larger financial platform like TradingView.
Bioventus, Inc. Class A Actuals & Estimates (NASDAQ:BVS)
This article provides an overview of Bioventus Inc. (NASDAQ: BVS) stock, including its current price, historical performance, analyst forecasts, and financial data. It details the company's market capitalization, volatility, recent earnings, revenue figures, and upcoming earnings report date. The article also confirms that BVS does not pay dividends and offers technical analysis ratings.
Price to earnings forward of Bioventus, Inc. Class A – FWB:4B8
The article provides information on the "Price to earnings forward" metric for Bioventus, Inc. Class A (FWB:4B8) on the Frankfurt Stock Exchange. It indicates no current trading activity with the market closed, and the specific value of the metric is listed as "Period Value Change Change % Made by humans" which suggests a placeholder or dynamic content not fully rendered.
Price to earnings forward of Bioventus, Inc. Class A – TRADEGATE:4B8
This article displays the "Price to earnings forward" value for Bioventus, Inc. Class A (4B8) on the Tradegate Exchange. It indicates that the market is closed with no current trades. The data is provided by ICE Data Services and FactSet.
Bioventus, Inc. Class A Actuals & Estimates (FWB:4B8)
This article provides an overview of Bioventus, Inc. Class A (FWB:4B8) stock, including financial actuals and estimates. It addresses frequently asked questions about its stock ticker, price forecasts, historical highs and lows, earnings reports, revenue, net income, dividends, and employee count. The stock forecast indicates a maximum estimate of 13.79 EUR and a minimum of 12.06 EUR.
4B8 Forecast — Price Target — Prediction for 2027
This article provides a forecast for Bioventus, Inc. Class A (4B8) stock, including analyst price targets, historical highs and lows, and financial performance data. It details the company's past earnings and revenue surprises, upcoming earnings dates, and current employee count. The article also confirms that 4B8 does not pay dividends.
Enterprise value to EBITDA forward of Bioventus, Inc. Class A – FWB:4B8
This article provides the enterprise value to EBITDA forward for Bioventus, Inc. Class A (FWB:4B8) on the Frankfurt Stock Exchange. It indicates that the market is currently closed with no trades. The page is part of a financial data service, likely TradingView, offering an overview of the company's financials.
Bioventus, Inc. Class A Trade Ideas — FWB:4B8
This article compiles several trading ideas for Bioventus, Inc. Class A (FWB:4B8, NASDAQ:BVS), highlighting its potential for growth and innovation in the healthcare sector. Analysts point to the company's strong financial performance in Q3 2023, management changes, and strategic contracts for products like DUROLANE® as reasons for optimistic investment outlooks, with some even suggesting a $45 target price. Investors are advised to conduct their own due diligence.
Book value per share of Bioventus, Inc. Class A – FWB:4B8
This article provides access to the book value per share of Bioventus, Inc. Class A, trading on the Frankfurt Stock Exchange under the ticker FWB:4B8. It indicates that the market is closed with no trades. The content also lists various features and services offered by TradingView, the platform on which this information is hosted.
After tax other income/expense of Bioventus, Inc. Class A – TRADEGATE:4B8
This article is a financial data page from TradingView, displaying the "After tax other income/expense" for Bioventus, Inc. Class A (TRADEGATE:4B8). It indicates that the market was closed with no trades showing for the selected period. The page also features standard navigation and copyright information typical of a financial data platform.
Asset turnover of Bioventus, Inc. Class A – TRADEGATE:4B8
This article displays the asset turnover information for Bioventus, Inc. Class A, trading under the symbol 4B8 on the Tradegate Exchange. It indicates that the market was closed with no trades recorded for this particular metric. The content primarily focuses on the financial overview for the company on the TradingView platform.
EBIT per share of Bioventus, Inc. Class A – TRADEGATE:4B8
The article provides financial information for Bioventus, Inc. Class A (TRADEGATE:4B8), specifically focusing on its EBIT per share. It is presented in the context of TradingView's platform, which offers various market data and financial tools. The content highlights the company's stock information and acknowledges the data providers.
Bioventus, Inc. Class A Statistics – TRADEGATE:4B8
This article provides key financial statistics for Bioventus, Inc. Class A (TRADGATE:4B8), including valuation ratios like price-to-sales and enterprise value to EBITDA. It notes the company employed 930 people as of 2025 and presents a detailed breakdown of annual and quarterly metrics, though most specific data points are listed as "—". The content emphasizes various financial ratios, profitability, liquidity, and solvency metrics.
